No Picture
Trading Ideas

Halliburton Shuts Venezuela Work as Trump Steps Up Pressure

(Bloomberg) — Halliburton Co. is shutting down primary operations in Venezuela as the U.S. tightens sanctions against the Nicolas Maduro regime.“Through December 1, 2020, we are only permitted to perform certain transactions and activities necessary for safety or the preservation of assets in Venezuela, along with other administrative activities,” the company said Friday in a federal filing. “It is unlikely that we will be able to remove our assets that remain in Venezuela and those assets may be expropriated.”The Trump administration is ratcheting up pressure on Maduro’s regime as the country reels from the Covid-19 pandemic and the lowest oil …read more […]

No Picture
Trading Ideas

3 Monster Growth Stocks Gearing up for Gains

Just when it looked like time to throw in the towel, the market pulled through and delivered a win. Stabilizing crude oil prices, a few better-than-expected earnings reports as well as the possibility of a fresh fiscal stimulus package all helped inspire confidence among investors.While April’s rally doesn’t necessarily signal that the worst is behind us, it’s encouraging to say the least. Add in the opportunity to find exciting growth plays, and you have our attention.According to the Wall Street pros, even amid the ongoing public health crisis, a select group has set itself up for growth to the upside, …read more […]

No Picture
Trading Ideas

AT&T announces John Stankey will become CEO on July 1

Randall Stephenson, AT&T’s current CEO, said Friday he will retire, but will serve as executive chairman of the board until January 2021. The announcement was made during AT&T’s virtual annual meeting. Stankey oversaw WarnerMedia after AT&T’s $85 billion purchase of media company Time Warner. …read more […]

Newsmakers

CytoDyn to Hold Conference Call to Provide Updates on Completion of BLA Filing for HIV, Timeline for Potential Approval of Treatment for COVID-19 Patients, and Two Publications, Including The New England Journal of Medicine

VANCOUVER, Washington, Apr 24, 2020  — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that […]